Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBIT Margin: 2019-2025

Historic EBIT Margin for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -15.96%.

  • Legend Biotech's EBIT Margin rose 2796.00% to -15.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -32.82%, marking a year-over-year increase of 3658.00%. This contributed to the annual value of -0.40% for FY2024, which is 8418.00% up from last year.
  • As of Q3 2025, Legend Biotech's EBIT Margin stood at -15.96%, which was up 68.70% from -50.98% recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's EBIT Margin ranged from a high of 21,716.39% in Q4 2024 and a low of -184,760.17% during Q4 2023.
  • For the 3-year period, Legend Biotech's EBIT Margin averaged around -14,905.59%, with its median value being -53.42% (2025).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by 18,425,141bps in 2023, then spiked by 20,647,656bps in 2024.
  • Quarterly analysis of 5 years shows Legend Biotech's EBIT Margin stood at -228.07% in 2021, then tumbled by 28,068bps to -508.75% in 2022, then tumbled by 18,425,141bps to -184,760.17% in 2023, then soared by 20,647,656bps to 21,716.39% in 2024, then spiked by 2,796bps to -15.96% in 2025.
  • Its EBIT Margin stands at -15.96% for Q3 2025, versus -50.98% for Q2 2025 and -53.42% for Q1 2025.